在可操作的HPV阴性头癌中使用新辅助剂capecitabine:在资源有限的环境中偶然发现
Marco A Mascarella1,2,3, Keith Richardson1, Alex Mlynarek1
1Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
概括
新辅助剂capecitabine (NC) 在人乳头瘤病毒 (HPV) 阴性头角状细胞癌 (HNSCC) 中显示出病理反应. 这种方法可能有利于资源有限的医疗保健机构的患者.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症研究研究
- 临床试验 临床试验
背景情况:
- 人类乳头瘤病毒 (HPV) 阴性头角状细胞癌 (HNSCC) 的治疗仍然具有挑战性.
- 在公共卫生保健系统中,及时获得护理往往是有限的,这可能导致治疗前疾病进展.
研究的目的:
- 评估新辅助剂capecitabine (NC) 对可手术HPV阴性HNSCC的临床到病理阶段迁移的影响.
- 为了比较经过手术后的NC与标准护理 (SC) 的结果,在一个阶段匹配的队列中.
主要方法:
- 接受NC的16名患者的前性队列与接受SC的32名相应阶段的患者进行了比较.
- 这项研究是在加拿大蒙特利尔的两个学术中心进行的.
- 使用修改后的瑞安得分来评估病态治疗反应.
主要成果:
- 与标准治疗 (SC) 相比,新辅助剂capecitabine (NC) 导致显著的临床到病理阶段迁移 (P=.0047).
- 16名NC患者中有10人表现出病理反应 (1个完整,3个主要,6个轻微).
- 与capecitabine没有观察到严重的治疗毒性,所有NC患者都进行了手术.
结论:
- 经过手术后的新辅助性capecitabine (NC) 在HPV阴性HNSCC中显示出可测量的病理反应.
- 这种治疗策略在资源有限的医疗机构中显示出潜在的实用性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...